Wedbush analyst David Nierengarten raised the firm’s price target on Disc Medicine (IRON) to $110 from $90 and keeps an Outperform rating on the shares. The firm notes the company received a Commissioner’s National Priority Voucher, reducing drug application review time for bitopertin to 1-2 months. Wedbush expects FDA to decide on Priority Review for bitopertin in EPP/XLP in late November/early December based on a September 30 NDA submission, which could imply regulatory approval by early February 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch
- Disc Medicine receives CNPV from FDA for Bitopertin
- Disc Medicine Board Member Mona Ashiya Resigns
- Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment
- Promising Developments and Positive Trials Support Buy Rating for Disc Medicine’s Bitopertin